Kym Tisder

Kym Tisder

Associate

Kym Tisder is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she focuses on corporate matters, securities law, and the formation and operation of venture capital funds and other private investment funds. She works with clients across all stages of growth, from start-ups to established public companies.

During law school, Kym participated in the Entrepreneurship and Innovation Clinic, where she gained corporate law experience.

Experience

During law school, Kym participated in the Entrepreneurship and Innovation Clinic, where she gained corporate law experience.

Education

J.D., Yale Law School, 2021
M.B.A., Yale School of Management, 2021
B.S., Finance, DePaul University, 2015

Admissions

State Bar of California

Credentials

Education

J.D., Yale Law School, 2021
M.B.A., Yale School of Management, 2021
B.S., Finance, DePaul University, 2015

Admissions

State Bar of California

Recent Insights

Client Highlights

On April 22, 2024, Rubedo Life Sciences, a Sunnyvale, CA-based biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells that drive age-related diseases, closed a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors. Wilson Sonsini Goodrich & Rosati advised Rubedo on the transaction.

Learn More

Client Highlights

On February 27, 2024, California-based Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, announced that it has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. Denali Therapeutics anticipates gross proceeds from the PIPE to be approximately $500 million. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.

Learn More